10 Stocks Worth Watching This Week: Warsh's Debut and the Post-SpaceX Reset — June 15–19, 2026

Market context: a week defined by two events

Two events bookend this trading week, and both reset the calculus.

The first is Wednesday's FOMC decision, where new Fed Chair Kevin Warsh will deliver his first post-meeting press conference. The mechanical outcome is near-certain — rates stay at 3.50–3.75%, the SEP gets refreshed, life moves on. The signal investors are actually paying for is tone. Warsh inherits a Fed under political pressure from a White House that wants cuts, an inflation print at a three-year high, and a labor market that refuses to crack. Forbes and CNBC are already trailing the possibility that the FOMC drops its easing bias entirely, and a small but growing camp is pricing the tail risk of a 2026 hike. That single word change in the statement is the most important macro variable on the calendar.

The second is the SpaceX IPO aftermath. Friday's debut priced $75 billion at $135, opened at $150, peaked near $176, and closed at $161 — a $2 trillion-plus market cap that briefly made Elon Musk the world's first trillionaire. The "halo trade" lasted less than a session. By Friday afternoon, capital was rotating out of public space peers — Rocket Lab (-13%), AST SpaceMobile (-15%), Intuitive Machines, Redwire — and into the new megacap. The question this week is whether that flow reverses, stabilizes, or accelerates.

Layer on top: a holiday-shortened week (Juneteenth Friday), light earnings calendar (Kroger, Accenture, Jabil, CarMax, Smith & Wesson, Progressive), retail sales Wednesday morning, and the ongoing slow burn of Israel-Iran tensions and Trump's $1.5 trillion FY27 defense budget proposal still circulating on Capitol Hill.

Here are the ten stocks worth your attention.

1. Northrop Grumman (NOC) — ~$525 · Long-term conviction

The cleanest pure-play on the Trump defense budget cycle. Northrop owns the B-21 Raider program (next-gen stealth bomber, production ramping), the Sentinel ICBM replacement, classified space contracts, and a meaningful slice of the Golden Dome homeland missile defense architecture that's been quietly moving through DoD planning since the spring. Backlog sits north of $90 billion. With Trump's proposed $1.5T FY27 defense budget headed for HASC markup this summer, primes with deep modernization exposure are positioned to compound regardless of the Fed's tone.

This week's catalyst: Defense appropriators continue FY27 conversations; any Warsh hawkish signal that pressures growth multiples tends to help defense names, which trade on backlog visibility rather than rate-sensitive earnings.

Key risk: Sentinel cost overruns remain a Pentagon sore point; another DoD critical-review headline would cap upside.

Timeframe: Long-term (12–36 months).

2. Cameco (CCJ) — ~$101 · Long-term conviction

The nuclear renaissance is one of the few secular themes where the supply story is as compelling as the demand story. Cameco controls Cigar Lake and McArthur River — the world's highest-grade uranium deposits — and just announced (June 1) an increased ownership stake in Cigar Lake. Add the 49% Westinghouse stake, which captures reactor service revenue from every new build and life-extension globally, and you have a vertically integrated bet on AI-driven power demand, energy security re-shoring, and small modular reactor deployment. The recent ~20% pullback is gift-wrapped entry.

This week's catalyst: Spot uranium has been bid back toward $90/lb; any utility contracting headline or US enrichment policy update (Centrus DOE Phase III contract expires June 30) drags the whole sector higher.

Key risk: Uranium spot can move 15% in either direction on thin volume; near-term volatility is structural.

Timeframe: Long-term (24–60 months).

3. Eli Lilly (LLY) — ~$890 · Long-term conviction

The GLP-1 thesis is no longer a secret, but the durability of Lilly's lead is still underpriced. Mounjaro and Zepbound have outpaced Novo's Wegovy on real-world weight-loss data, oral orforglipron is approaching FDA decision, and the pipeline into Alzheimer's (donanemab), oncology (Verzenio), and cardiometabolic combinations is the deepest in big pharma. In a week where the macro picture is uncertain and growth multiples wobble, Lilly's secular tailwinds and pricing power make it the rare large-cap that compounds through rate uncertainty.

This week's catalyst: No company-specific event, but defensive growth names with durable earnings tend to outperform on hawkish FOMC days — Lilly has historically been one of the cleanest expressions of that trade.

Key risk: Compounded GLP-1 pricing pressure and Medicare negotiation overhang on orals.

Timeframe: Long-term (24–60 months).

4. Kroger (KR) — ~$70 · Swing/catalyst

Q1 earnings drop pre-market Thursday June 18. The setup is unusually clean: consensus is $1.47 EPS on $45.3B revenue, sell-side is positioned cautiously after April's weaker-than-expected sales commentary, and the Albertsons unwind premium has fully bled out of the stock. Wednesday morning's retail sales print sets the tone — a soft May number actually helps Kroger relative to discretionary peers, because grocery share rises as consumers trade down.

This week's catalyst: Q1 earnings + management commentary on Q2 SSSG trajectory and digital margin.

Key risk: Any guidance cut on full-year EPS would extend the technical breakdown below the 200-DMA.

Timeframe: Swing (5–15 trading days).

This is where the analysis gets actionable. AlphaBriefing members get the full investment framework — scenarios, positioning, and the bottom line.

Subscribe to AlphaBriefing — Free, Member, and Paid tiers available.